Navigation Links
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
Date:5/25/2011

Esbriet as follows: Germany in September of 2011; France, Spain and Italy during the first half of 2012 and the United Kingdom by mid-2012.  InterMune plans to have a focused organization in Europe of approximately 125 full-time personnel by the end of 2012, supported by expert consultants and third-party service providers.  InterMune will provide an update at the meeting and on the webcast on the company's launch preparations for Esbriet in Europe.

ASCEND: New Phase 3 Trial

During the meeting, Bill Bradford, Senior Vice President of Clinical Science and Biometrics, will provide an update on InterMune's new Phase 3 study named ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF). ASCEND will add to pirfenidone's body of clinical evidence and support a future submission for FDA approval.

ASCEND will be a randomized, 52-week placebo-controlled trial with a primary endpoint of change in forced vital capacity (FVC), a key measure of lung function, between baseline and Week 52. The trial will enroll approximately 500 IPF patients with mild-to-moderate impairment in lung function who will be randomly assigned to receive oral pirfenidone (2403 mg/day) or placebo. More details will be provided at the meeting and on the webcast.

Primary enrollment will take place in the U.S. with additional centers in Mexico, South America, Australia and New Zealand, across more than 140 investigational sites in total. InterMune expects to begin enrollment in ASCEND in June 2011, with all trial participants fully enrolled by the first half of 2012.  InterMune anticipates a New Drug Application (NDA) resubmission for pirfenidone in the second half of 2013 and an FDA action in the first half of 2014.  

Guidance for 2011 Expenses

InterMune also will discuss at the Analyst Day its 2011 financial guidance for operating expenses.  The company today provided its forward-looking expense guidance fo
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
2. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
3. InterMune to Present at J.P. Morgan Healthcare Conference
4. InterMune Reports Third Quarter 2010 Financial Results
5. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
6. InterMune to Release Second Quarter Financial Results on July 27
7. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
8. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
9. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
10. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
11. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 29, 2014  BioMed Realty Trust, Inc. (NYSE: ... focusing on life sciences, today announced financial results ... Third Quarter 2014 Highlights Financial and ... transactions during the quarter representing approximately 657,700 square ... the third quarter of approximately 219,700 square feet; ...
(Date:10/27/2014)... MENLO PARK, Calif. , Oct. 27, 2014 /PRNewswire/ ... isolation of blood flow and delivery of fluids to ... the RenovoRx Board of Directors has appointed Shaun ... additional Member of the RenovoRx Board of Directors. Bagai ... medical technology industry. Bagai joined RenovoRx in ...
(Date:10/27/2014)... , Oct. 27, 2014 Research and Markets ... Vaccines Market 2014-2018" report to their offering. ... caused by a variant of the swine H1N1 virus, known ... which infects nose, throat, and lungs. H1N1 virus is an ... infect different animal species such as humans, swine, birds, seals, ...
Breaking Medicine Technology:BioMed Realty Trust Reports Third Quarter 2014 Financial Results 2BioMed Realty Trust Reports Third Quarter 2014 Financial Results 3BioMed Realty Trust Reports Third Quarter 2014 Financial Results 4BioMed Realty Trust Reports Third Quarter 2014 Financial Results 5BioMed Realty Trust Reports Third Quarter 2014 Financial Results 6BioMed Realty Trust Reports Third Quarter 2014 Financial Results 7BioMed Realty Trust Reports Third Quarter 2014 Financial Results 8BioMed Realty Trust Reports Third Quarter 2014 Financial Results 9BioMed Realty Trust Reports Third Quarter 2014 Financial Results 10BioMed Realty Trust Reports Third Quarter 2014 Financial Results 11BioMed Realty Trust Reports Third Quarter 2014 Financial Results 12BioMed Realty Trust Reports Third Quarter 2014 Financial Results 13BioMed Realty Trust Reports Third Quarter 2014 Financial Results 14BioMed Realty Trust Reports Third Quarter 2014 Financial Results 15BioMed Realty Trust Reports Third Quarter 2014 Financial Results 16BioMed Realty Trust Reports Third Quarter 2014 Financial Results 17BioMed Realty Trust Reports Third Quarter 2014 Financial Results 18BioMed Realty Trust Reports Third Quarter 2014 Financial Results 19BioMed Realty Trust Reports Third Quarter 2014 Financial Results 20BioMed Realty Trust Reports Third Quarter 2014 Financial Results 21RenovoRx Board Names Shaun R. Bagai as CEO 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3
... Digital Assent, provider of the award-winning PatientPad® self-service ... that it has appointed Frank Garland as vice president ... Garland will focus on increasing the digital advertising and ... the company,s New York sales office. "Frank ...
... Oct. 20, 2011 Bend Research Inc. ( www.bendresearch.com ... has announced that John McLeod has joined the company ... http://photos.prnewswire.com/prnh/20111020/CL87178 ) McLeod was formerly Director ... six years, where his strategic vision is credited with ...
Cached Medicine Technology:Digital Assent Names Frank Garland Vice President of Advertising Sales 2Bend Research Announces New Chief Financial Officer 2
(Date:10/30/2014)... Lauderdale, FL (PRWEB) October 30, 2014 ... US Joint Commission Accredited teleradiology and specialty telemedicine ... that in addition to its existing teleradiology services ... multispecialty second opinion and expert telemedicine services, to ... Texas. , As a result of this innovative ...
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... When it comes to heart disease, a new study finds ... they have symptoms that spell trouble. "The main danger ... more severe or advanced stage of heart disease, there are ... Fulbright Scholar and research fellow at the Harvard School of ... and Stroke Foundation of Canada. In the study, researchers ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 (HealthDay ... your health, a new study reports. Previous research has ... and prevent osteoporosis. These benefits to bone health have led ... healthy diet. But this new study found that drinking ... from bone fractures, and was linked to an overall higher ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Americans, opinions about the ... a new study finds. Democratic voters are strongly ... to the researchers. Almost three-quarters of Democrats want the ... percent want Congress to implement the current law, while ... ACA. Among Independent voters, one-third want the law ...
Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... Your Way, Contest and More than ... $10,000 in Cash and Prizes, HOFFMAN ESTATES, ... is the grand prize winner of the,annual "New Day Your Way" contest, ... and achieve their fitness goals,in 2008. During the 12-week contest, Kmart provided ...
... Researchers from the John Innes Centre and the University ... function of an enzyme which is involved in decorating ... variety of different carbohydrate molecules attached to them which ... the target organism or overcome resistance. By manipulating ...
... iron and offers a good set of proteins. This ... Eklund-Jonsson at the Department of Food Science, Chalmers University of ... a whole-grain product with high folate content. It is ... cardiovascular diseases, and it is also believed that it protects ...
... More Than $270 Million in Combined ... WALTHAM, Mass., May 28 Decision Resources, one ... pharmaceutical and,healthcare issues, forecasts that the Chinese type 2 ... to the new Emerging Markets report,entitled Type 2 Diabetes ...
... reach of drugs , , WEDNESDAY, May 28 (HealthDay News) ... provides a "hideout" for HIV during drug treatment and is ... cells (FDCs) are located throughout the body in specialized sites ... and Johns Hopkins School of Medicine. , FDCs act as ...
... of Recent Acquisitions; Continued Focus on ... Operational Efficiencies, SHENZHEN, ... NPD ) (,Nepstar, or ,the Company,), the,largest retail drugstore chain in ... March 31, 2008., Financial Highlights, For the first ...
Cached Medicine News:Health News:The Weight Is Over: Five Winners Lose 194 Pounds as Kmart Encourages 24,000 Americans to Achieve Healthier Lifestyle 2Health News:China's Type 2 Diabetes Drug Market Will More than Triple by 2012 2Health News:Scientists Break Into HIV 'Hideout' 2Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 2Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 3Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 4Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 5Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 6Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 7Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 8Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 9Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 10Health News:China Nepstar Chain Drugstore Reports Net Income Growth of 304.4% for First Quarter 2008 11
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... lightweight brace is designed for the ... fractures. The anatomically correct design achieves ... for optimal control of ulnar segments. ... motion is permitted to prevent problems ...
Finger /Thumb Splint has a stay that may be shaped to hold finger or thumb in exact degree of flexion. It also has a contact closure....
... joint or DIP joint flexioncontractures of any degree. ... gel-lining cushions injured fingers so treatment to straighten ... more successful therapy results. Use during the day ... maintain gains in motion. Available in small, medium ...
Medicine Products: